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ABSTRACT
The objective of this clinical trial was the analysis of 2 methods for engineering of autologous bone grafts
for maxillary sinus augmentation with secondary implant placement. Group 1 (8 patients, 12 sinuses):
cells of mandibular periosteum were cultured in a good manufacturing practice laboratory (2 weeks)
with autologous serum and then transferred onto a collagen matrix. After another week, these composites
were transplanted into the sinuses. In group 2A (2 patients, 3 sinuses), cells of maxillary bone were
cultivated with autologous serum for 2 weeks, seeded onto natural bone mineral (NBM, diameter
[Ø]¼ 8 mm) blocks, and cultivated for another 1.5 months. These composites were transplanted into the
sinuses. Group 2B (control, 3 patients, 5 sinuses) received NBM blocks alone. In the course of implant
placement 6 (group 1) and 8 (group 2) months later, core biopsy were taken. Clinical follow-up period
was 1 to 2.5 years in group 1 and approximately 7 years in groups 2A and 2B. New vital bone was found
in all cases at median densities of 38% (n¼ 12) in group 1, 32% in group 2A (n¼ 3), and 25% in group 2B
(n¼ 5). Differences between group 1 and 2B as well as 2A and 2B were statistically significant ( p¼ 0.025).
No adverse effects were seen. All methods described were capable of creating new bone tissue with
sufficient stability for successful implant placement.
INTRODUCTION
AUTOGENOUS BONE GRAFTS are considered to be osteo-conductive and osteoinductive. Autogenous bone
grafting remains the gold standard for the augmentation of
the maxillary sinus before placement of dental implants.1–6
It is desirable to avoid harvesting of excessive amounts
of bone to reduce donor site morbidity.7 Non-vital bone
substitutes such as xenogenic deproteinized natural bone
mineral (NBM, BioOss, Geistlich Pharma AG, Wolhusen,
Switzerland) or others avoid bone harvesting but are sup-
posed to have a narrow range of use and limited potential of
osteoconduction.8,9 Requisites for the use of NBM include
the proximity of vital bone and a good blood supply. These
requirements are present in the sinus lift model.10 Methods
of tissue engineering and the application of differentiation
factors such as bone morphogenetic protein have seen
significant advances in recent times.11–14 In a clinical trial
involving sinus floor augmentation, it was reported that
platelet-rich plasma could support bone regeneration when
added to beta-tricalciumphosphate (beta-TCP).15 The
combination of non-vital bone substitutes and autogenous
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bone precursor cells or osteoblasts may provide a further
option for sinus augmentation.
The aim of the present trial was the comparative study of
an ex vivo tissue-engineered combination of a collagen
matrix and autologous periosteal cells and the ex vivo tissue-
engineered combination of NBM with autologous osteo-
blasts in a sinus augmentation procedure with secondary
implant placement.
MATERIALS AND METHODS
The following patient groups with atrophy of the poste-
rior maxilla were studied (Table 1):
Group 1: Combination of periosteum-derived cells with a
collagen matrix; n¼ 8 patients (4 male, 4 female, age:
51.4–65.2 years, mean 57.8 years), n¼ 12 sinus aug-
mentation procedures (3 bilateral), n¼ 30 core biopsies;
time of implant placement: 6 months; implant: Replace
Select Straight (Nobel Biocar, Ko¨ln, Germany); clinical
follow-up period: 1–2.5 years.
Group 2A: Combination of autologous osteoblasts and
xenogenic NBM blocks (BioOss, Ø¼ 8 mm), n¼ 2 pa-
tients (age: 43/56 years), n¼ 3 sinus augmentation pro-
cedures (1 bilateral), n¼ 3 core biopsies; time of implant
placement: 8 months; implants: Sustain-HA-‘‘Plasma
sprayed’’ implants (Lifecore Biomedical, Sascha, MN);
clinical follow-up period: 7 years.
Group 2B: NBM alone (control), n¼ 3 patients (age: 46–58
years), n¼ 5 sinus augmentation procedures (2 bilateral),
n¼ 5 core biopsies; time of implant placement: 8 months;
implants: Sustain-HA-‘‘Plasma sprayed’’ implants (Life-
core Biomedical); clinical follow-up period: 7 years.
Harvesting of autologous tissue
and cell culture group 1
Four hundred fifty mL of whole blood was drawn, and
100 mL autologous serum was generated 2 days before initial
surgery. Periosteum (11 cm) was taken from the lateral
cortex of the mandibular angle with local anesthesia and
processed in a Good Manufacturing Practice laboratory.
Periosteal tissue was divided into small fragments and di-
gested with 0.25% collagenase P (Sigma, Germany) in alpha
medium (Invitrogen, Karlsruhe, Germany) for 4 h at 378C and
filtered through a 70-mm cell strainer (Falcon). The cell filtrate
was centrifuged at 1800 rpm for 10 min. Pellets were re-
suspended in alpha medium supplemented with 20% patient
serum and 100 U/mL penicillin G, 100mg/mL streptomycin,
and 0.25mg/mL amphotericin (Invitrogen). The cell number
was counted, and cells were plated in a 75-cm2 flask and
incubated at 378C with 5% carbon dioxide. The medium was
replaced every 2 days. After reaching confluence, cells were
trypsinized with a 0.25% trypsin/ethylenediaminetetraacetic
acid solution (Invitrogen). The cells were subcultured again
at day 8 to day 11 and seeded on to a collagen scaffold
(1.5105 cells/cm2) (Lyostypt, Braun) at day 12 to day 15.
Four of these composites (23.5 cm in size) were prepared
for each sinus and cultivated with differentiation medium
(alpha medium containing 10% patient serum, 100 nM dexa-
methasone, 10mM b-glycerophosphate, 25mg/mL ascorbic
acid, 100 U/mL penicillin G, 100mg/mL streptomycin,
and 0.25mg/mL amphotericin) for another 5 to 7 days. This
amounted to a total of approximately 21 days between har-
vesting of periosteum and sinus augmentation with the
composites.
Harvesting of autologous tissue
and cell culture group 2
Blood was drawn, and autologous serum was generated.
Autologous bone was taken from the maxillary tuberos-
ity.16 The bone chips were processed as described previ-
ously1,17,18 in modified standard Dulbecco’s modified
Eagle medium (ICN-flow, Sigma, St. Louis, MO) replacing
fetal bovine serum with human autologous serum.17 After
2 weeks of in vitro culture, the osteoblast-like cells were
inoculated in F75 plastic tissue culture flasks (Falcon,
Becton-Dickinson & Co., Plymouth, UK). After another
week, sub-confluence was reached, and the osteoblast-like
cells were seeded onto cubic fragments of Bio-Oss (Ø¼
8 mm) of approximately 8 mm3 at a density of 3.3106/
cm2 and were cultivated for another 40 days on 24-well
plates (Costar). To determine alkaline phosphatase (ALP)
activity, cells were seeded at 1103 cells/cm2 in Lab-Tek
chamber slides (Nunc, Denmark), and cultured for 3 days.
ALP activity was determined using cytochemistry with the
Sigma Diagnostic Kit (86-R, Deisenhofen, Germany), as
described previously.1
TABLE 1. PATIENTS WITH ATROPHY OF THE POSTERIOR MAXILLA WERE STUDIED
Group
Origin
of cells Matrix
Patients
(n)
Sinus
augmentation
procedure (n)
Biopsies
(n)
Time of implant
placement (months)
Follow-up
period (years)
1 Periosteum Collagen 8 12 30 6 1–2.5
2A Bone NBM 2 3 3 8 7
2B None NBM 3 5 5 8 7
Details and implant types are described within the materials and methods section. NBM, xenogenic natural bone mineral blocks (BioOss).
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Sinus augmentation
All surgical procedures were performed in the outpatient
clinic using local anesthesia. A crestal incision was used,
vertically extended down to the mobile mucosal border, and
the facial aspect of the sinus wall was exposed. With refer-
ence to the virtual apex line, the inferior border of the lateral
window was marked using round burs. After removal of
the bone, the sinus membrane was elevated. Then tissue-
engineered bone substitutes (group 1: 4 cellþ collagen-
composites/sinus; group 2A: 12–14 cellþNBM composites/
sinus; group 2B: NBM granula [Ø¼ 1–2-mm]) were im-
planted, and the soft tissue was repositioned and sutured
with 5-0 Vicryl (Ethicon GmbH, Norderstedt, Germany). On
the tenth postoperative day, the sutures were removed. In all
cases, the postoperative healing was uneventful. After 6
months, core biopsies were taken using hollow trephine burs
(3.56 mm) in the course of implantation. Each patient re-
ceived at least 2 implants per augmented area. (For number
of implants and core biopsy, see above.)
Histology
Preparation of non-decalcified specimens and histologi-
cal analysis was performed as described previously.19–21
Specimens were dehydrated in a graded fashion with al-
cohol and embedded in methylmethacrylate blocks. Non-
decalcified serial sections were prepared and ground to a
width of 80 mm for microradiography and a 8 mm for
staining (Toluidine-blue).19–21 In group 2A and 2B, 80-mm
sections were prepared and stained with toluidine blue and
basic fuchsin. Viable bone stains more intensely than NBM
when using toluidine blue and basic fuchsin (Fig. 1). The
presence of osteocytes could further help to identify viable
bone.
Microradiography was performed for samples from group 1
(3 mAs, 25 kV, time of exposure: 10 min, material: high
resolution plates, Kodak, Faxitron, Rohde and Schwarz
GmbH and CoKG, Ko¨ln, Germany)20 and the images ana-
lyzed using a digital image analyzing system (group 1: Osiris
program, digital imaging unit, Center for Medical Informat-
ics, University of Geneva, Switzerland; group 2: Image J 1.32,
National Institutes of Health). Specifically, the bone-covered
space in the region of interest was analyzed with respect to the
non-mineralized medullary space in percentage of mineral-
ized bone matrix per area (3 repeats, variation< 2%, mag-
nification: 40)(bone density; unit: [%]).20,22,23
Statistics
Statistical evaluation was performed according to Kruskal-
Wallis to detect differences between groups 1, 2A, and 2B.
Two-tailed Mann-Whitney U-tests served to evaluate differ-
ences between groups 1 and 2A and groups 2A and 2B, as well
as differences between female and male patients of group 1.
Level of significance was defined at p< 0.05.
Ethics
The ethics committee of the University of Erlangen
(group 1, approval no. 2741–2001) and the Centro Nazio-
nale per la Ricerca (group 2, approval no. 95.02288.CT04–
1995, Veneta Health Research Project number 1798 of
23.4.1996) approved the study.
RESULTS
Cell culture group 1
At day 5 through day 8 after the first passage, an average
of 1106 adherent cells were present. Cell numbers increased
to more than 20 million during the second week (average
2.1107). At day 12 to day 15, cells were harvested and
implanted into a collagen matrix (Lyostypt, Braun) at a den-
sity of 1.5105/cm2. Approximately 6 million cells were
FIG. 1. Core biopsy (T) of group 2A. Toluidine blue and basic
fuchsin stain of an 80-mm non-decalcified section. The higher
magnification showed natural bone mineral (NBM) particles (BM)
incorporated by newly formed bone (B), the latter of which is
stained darker than NBM particles. Upper line: 2 mm, lower line:
200 mm. Color images available online at www.liebertpub.com /
ten.
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implanted into 4 sheets of collagen (42.5 cm in size). After
another week of culture, 4 sheets of collagen were transferred
into each sinus.
Cell culture group 2A
Cells were subcultured to a density of 3.3106/cm2 be-
fore being transferred onto the NBM blocks. Cells were
defined as osteoblast-like cells by presence of ALP activity.
The total number of cells implanted into each sinus could
not be estimated because the cell/NBM composites were
subcultured for another 40 days.
Clinical results
All first-stage and second-stage surgeries were unevent-
ful. No infection was observed. Re-entry surgery was exe-
cuted 6 months (group 1) and 8 months (groups 2A and B)
after sinus augmentation. At this time, a sufficient quan-
tity of mineralized tissue was found in groups 1 (Fig. 2), 2A
(Fig. 3), and 2B. Dental implants were placed without the
need for further bone augmentation (Figs. 2, 3). Implants
were left unloaded for 4 to 5 months before prosthetic re-
habilitation. None of the implants were lost in the observa-
tion period (group 1: 12–38 months, groups 2A, B: 7 years).
All implants remained firmly osseointegrated throughout the
experimental period.
Light microscopy
Core biopsy of group 1 showed vital woven and partly
mature lamellar bone (Fig. 4). Little of the collagen matrix
remained.
Core biopsy of group 2A showed that NBM particles were
incorporated in newly formed bone in the inferior part
(facing the former floor of the sinus) of the bone core
(*80% of bone core length) (Fig. 1). At the top of the biopsy
(*20%) poorly vascularized, dense connective tissue sur-
rounded NBM particles.
Core biopsy of group 2B showed bone cores with NBM
particles integrated with vital new bone. The density of
newly formed bone was significantly lower than in group
2A (see below).
Density of new bone within the former
cell-carrier composites
Group 1: The median bone density (mineralized tissue)
was 38% (minimum: 30%, maximum: 51%). Female pa-
tients (n¼ 4) had a tendency toward lower average bone
densities (median: 33%; minimum: 31%, maximum: 34%)
than male patients (n¼ 4; median: 40%; minimum: 30%,
maximum: 51%). These differences were not statistically
significant ( p¼ 0.245; Fig. 5).
Group 2A: The median density of newly formed bone
(disregarding NBM) was 32% (minimum: 30%, maximum:
37%). The median density of the complete mineralized
tissue (newly formed boneþNBM) was 43% (minimum:
34%, maximum: 45%; Fig. 5).
Group 2B: The median density of newly formed bone was
25% (minimum: 22%, maximum: 26%). The median density
of complete mineralized tissue (newly formed boneþ
NBM) was 38% (minimum: 35%, maximum: 70%; Fig. 5).
The Kruskal-Wallis test revealed significant differences
of density of newly formed bone between groups 1, 2A, and
2B ( p¼ 0.01). Differences between densities of newly
FIG. 2. Radiographs of a patient in group 1 before surgery (A),
6 months later (B), and after implant placement (C). At the time of
implant placement (B), a sufficient quantity of mineralized tissue
was found, and core biopsy showed new vital bone (Fig. 4). Ar-
rows show the floor of the sinus (point down) and limbus of the
alveolar ridge (point up).
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formed bone between group 2A (cellsþNBM) and 2B
(NBM) were statistically significant ( p¼ 0.025). Differ-
ences of densities of newly formed bone between groups 1
(cellsþ collagen) and 2A (cellsþNBM) were not statisti-
cally significant ( p¼ 0.18).
DISCUSSION
The aim of the present trial was to take steps into clinical
application of bone engineering techniques. The clinical
value of an ex vivo tissue-engineered combination of a
collagen matrix with autologous periosteal cells and the ex
vivo tissue-engineered combination of NBM with autolo-
gous osteoblasts was studied in patients in need of sinus
augmentation procedures. Implants were placed in a sec-
ond-stage surgery after 6 to 8 months because the alveolar
bone was not providing conditions offering primary sta-
bility of the implants in these patients.24
Methods of in vitro and in vivo tissue engineering of
bone and cartilage have been evaluated in a variety of
experiments, all showing potentials and limitations of these
methods.18,25–27 A major concern is the use of the proper
carrier matrix.
It has been suggested that absorbable scaffolds made of
the combination of undyed Vicryl (Polyglactin 910) and
undyed poly-p-dioxanon (Ethisorb fleece) or made of
polyglycolic acid fibers 15 mm in diameter would be ideal
for tissue engineering of bone and cartilage.13,14,28
There has been some concern about these polymers re-
garding decline in pH value during the degradation of the
polymers, which again, among many other shortfalls, may
bring about impaired cellular function and inhibition of
neoangiogenesis.13,29–31 Four months after posterior max-
illary augmentation with a combination of periosteum-
derived cells and Ethisorb fleece as a carrier material, other
authors observed sufficient osteogenesis in 18 of 27 pa-
tients.13 We tested the value of a variety of biomaterials for
the purpose of bone engineering in the course of an in vitro
FIG. 3. Radiographs of a patient in group 2 before surgery (A),
6 months later (B), and 7 years after implant placement (C). At the
time of implant placement, a sufficient quantity of mineralized
tissue was found, and core biopsy showed new vital bone (Fig. 1).
Arrows show the floor of the sinus (point down) and limbus of the
alveolar ridge (point up).
FIG. 4. Core biopsy (T) of group 1. Toluidine blue stain of an
8-mm non-decalcified section. The higher magnification shows
vital woven and partly mature lamellar bone (B). Upper line: 2 mm,
lower line: 200 mm. Color images available online at www.liebert
pub.com /ten.
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experiment and found 3-dimensional collagen scaffolds to
be most advantageous.32 Collagen is a significant constit-
uent of the natural extracellular matrix of bone and most
other tissues.33 Hemostatic properties, low antigenicity, and
moderate internal stability are some of its properties.34
Collagen scaffolds have been observed to promote cell at-
tachment, as well as 3-dimensional spread, and one follows
the course of natural de novo bone formation when using
collagen scaffolds for bone engineering.35,36
In group 1 of the present trial, a collagen matrix was used
for tissue engineering, resulting in bone formation in all
30 regions that were biopsied using a hollow trephine burr.
The mineralization rates were comparable with those
reached when using anterior and posterior iliac bone. Based
on the low number of patients (n¼ 8), the technique used in
group 1 appeared to have predictable results over a limited
time of follow-up.
Biomaterials such as xenogenous NBM provide good
internal stability of the implant, but complete absorption is
prolonged if not impossible.10,37,38 NBM is a finely crys-
talline apatite composed of calcium carbonate crystals sized
100 to 400 A˚ and arranged in a trabecular structure (pore
size: 300–1500 mm) that is highly porous (70–75%).38 NBM
and other bone substitutes are considered to be osteo-
conductive but not osteoinductive.9 Autogenous bone grafts
are considered to be osteoconductive and osteoinductive and
remain the gold standard in bone regeneration.3 Neither
xenogenic collagen nor NBM has a risk of transmitting
Creutzfeldt Jakob Disease.37 To avoid the potential risk of
transmitting prion diseases, autologous human serum in-
stead of fetal calf serum was used for the in vitro phases of
this trial.39
In the course of the in vitro phase of group 2A, we
confirmed again that osteoblast-like cells seeded on NBM
spread and express typical markers indicating osteoblast-
like differentiation, such as ALP.18,40 ALP is an enzyme
considered to be important in the process of biominerali-
zation.18,40 The patients tolerated the tissue-engineered
grafts well, and sufficient mechanical anchorage was es-
tablished for implant placement and loading. A limited
number of procedures (n¼ 3) and patients (n¼ 2), but a
7-year follow-up period, support these results.
In group 1 (cellsþ collagen) and group 2B (cellsþ
NBM), equivalent amounts of newly formed bone were
observed. The density was not significantly different be-
tween these groups but was statistically significantly higher
in group 1 and 2A than in group 2B (NBM). When adding
densities of remaining NBM to the bone densities of newly
formed bone, total densities of mineralized tissues were
43% in group 2A and 38% in group 2B. It remains con-
troversial whether the remaining NBM contributes to the
mechanical stability of the bony regenerate.10
A limitation of this study was the low number of proce-
dures and patients, especially in group 2A. An advantage
was a follow-up period of 7 years (group 2), showing no
implant failure and suggesting that ex vivo tissue-engineered
bone made using osteoblasts and NBM might be a clinical
option. More patients were enrolled in groups 1 and 2B. The
observation period of 1 to 2.5 years in group 1 showed
promising results with no implant loss. To meet statistical
criteria, we chose medians and mean ranks for data analysis.
Statistical analysis according to Kruskal-Wallis and the
Mann-Whitney U test are considered to be common methods
for small groups of samples.
Bone grafts, possibly mixed with NBM, have been con-
sidered to provide the most predictable results in the course
of sinus augmentation procedures. NBM has no os-
teoinductive properties. In former studies, we showed that
the addition of osteoinductive proteins or bone to NBM
improved the bone-implant contact (i.e., the osseointegra-
tion of implants) significantly, with the direct coverage of
the implant by newly formed bone being improved ap-
proximately 100%.10,41 The use of vital bone transplants is
known to reduce healing times and the time between aug-
mentation and implantation in cases of 2-step procedures.
We suggest that it is worthwhile to investigate new methods
of engineering bone transplants to save patients a second site
of invasive surgery, even when one is facing immense time
and effort for the patient and the doctor. Considering the
present technical possibilities, it will be difficult to shorten
the time needed to prepare the constructs used in group 1. In
the course of further comparative studies, it might however
be possible to reduce the time used for the cultivation of
the constructs in group 2A. It is possible that the use of
stem cells or certain cytokines such as bone morphogenetic
protein-2, -4, or -7 could provide shortcuts in the future.
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FIG. 5. Box plot (median, 1 and 3 quartile, range) showing
densities of newly formed bone of group 1 (cellsþ collagen),
group 2A (cellsþ natural bone mineral [NBM]) and group 2B
(NBM). When adding densities of remaining NBM to the bone
densities of newly formed bone, total densities of mineralized
tissues were 43% in group 2A and 38% in group 2B.
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The ex vivo tissue-engineered combination of a collagen
matrix and autologous periosteal cells and the ex vivo tissue-
engineered combination of NBM and autologous osteoblasts
could be shown to be of value in sinus augmentation pro-
cedures with secondary implant placement. We gave this
study the subtitle ‘‘steps into clinical application’’ because
we were examining a limited number of procedures and
patients. However, we suggest that, based on the present
findings, future clinical trials are warranted.
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